Use of physiologically relevant biopharmaceutics tools within the pharmaceutical industry and in regulatory sciences: Where are we now and what are the gaps?
Regulatory interactions are an important part of the drug development and licensing process. A survey on the use of biopharmaceutical tools for regulatory purposes has been carried out within the industry community of the EU project OrBiTo within Innovative Medicines Initiative (IMI). The aim was to capture current practice and experience in using in vitro and in silico biopharmaceutics tools at various stages of development, what barriers exist or are perceived, and to understand the current gaps in regulatory biopharmaceutics. The survey indicated that biorelevant dissolution testing and physiologically based modelling and simulation are widely applied throughout development to address a number of biopharmaceutics issues. However, data from these in vitro and in silico predictive biopharmaceutics tools are submitted to regulatory authorities far less often than they are used for internal risk assessment and decision making. This may prevent regulators from becoming familiar with these tools and how they are applied in industry, and limits the opportunities for biopharmaceutics scientists working in industry to understand the acceptability of these tools in the regulatory environment. It is anticipated that the advanced biopharmaceutics tools and understanding delivered in the next years by OrBiTo and other initiatives in the area of predictive tools will also be of value in the regulatory setting, and provide a basis for more informed and confident biopharmaceutics risk assessment and regulatory decision making. To enable the regulatory potential of predictive biopharmaceutics tools to be realized, further scientific dialogue is needed between industry, regulators and scientists in academia, and more examples need to be published to demonstrate the applicability of these tools.
Pharmaceutical Technology and Development, AstraZeneca R&D, Macclesfield, UK. Electronic address: Talia.Flanagan@AstraZeneca.com.
Talia
T
Flanagan
Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, Beerse, Belgium.
Achiel
A
Van Peer
Medical Products Agency, Uppsala, Sweden.
Anders
A
Lindahl
D001702:Biopharmaceutics; D003198:Computer Simulation; D004345:Drug Industry; D007880:Legislation, Drug; D008954:Models, Biological; D004364:Pharmaceutical Preparations / Q000737:chemistry; D012995:Solubility; D011795:Surveys and Questionnaires
D004364:Pharmaceutical Preparations
Biopharmaceutics; Biorelevant dissolution; Biowaivers; PBPK modelling